Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Welcome aboard... buckle up...record setting revenues and ELTP cash flow positive coming this quarter..
Great article... thanks for sharing
Thanks Doc.. I’m aware, but a few weeks ago we were told we needed to worry about it.. Same thing last year and it never developed.
I’m confused.. I was told to beware of tax loss season.. Isn’t the PPS suppose to go down during this time..??.. LOL LOL
Nice bunch for when the buy out comes
toohot future is so bright I got to wear shades..
The only talking point left is the PPS.. soon that will be taken care of.
Food for thought from two long term investors of Elite who are highly regarded here. This coming after our most recent launch.
Some thoughts from N2k
A final thought: Based on a strategic decision that totally realigned its product focus (and which cost additional shares to fund), Elite has become a well-diversified generics company. As a generics firm, the focus is on price not differentiation. SOX was an NDA and, thus, differentiated. It was a strategic anomaly and, I believe, a mistaken decision for a generics firm to make. But I forgive them the mistake because they are not attempting to escalate their financial commitment to an opioid product line that has socio-legal-political issues. Moreover, ADFs, while a grand idea, are and remain a costly drug. ICER has put out a report that indicates ADF opioids are overpriced by 40% and it is a major reason they will not gain the traction with the now cautious prescribers who do not believe their patients are at risk of abuse or diversion. Because the cost of ADF opioids is high, abuse threat low, and many of these people are on fixed incomes and sensitive to pricing, healthcare professionals will not easily prescribe ADFs.
And, there is the fact that the CNS ANDAs will be more profitable and reach a larger market.
So it is that we investors owe Nasrat and Elite a vote of thanks, respect and trust. Management is moving Elite toward success that early investors could not have imagined and it is because at a key tipping point they made a strategic decision that now finds the company with increasing revenues and on the doorstep of financial success. I am now invested in a better company than when I first began.
Some thoughts from WeeZuhl
Yesterday was the biggest day in the history of Elite Pharmaceuticals. We have never had any product with this much upside potential. It is particularly beneficial that the company has API quota in place and is ready to ship product within a few weeks to a distributor with the name and infrastructure to immediately start gaining market share. I say this is the "next phase" for two reasons: the IR and ER Adderall products will (1) make this company profitable (E is for earnings) and (2) allow further development without further dilution.
Congratulations to all long term investors. This is what we've been waiting for. Lots of investors have found this stock along the away, but I offer special praise to those investors with the insight and patience necessary to recognize the ongoing potential despite the recurrent setbacks. And while I am praising insight and patience, let's not forget Elite management. While the future of ADF opioids is in doubt, the future of Elite Pharmaceutical is very clear. For that fact alone, I give Nasrat Hakim great credit. I believe he showed true vision and was ahead of his peers in seeing problems in the ADF market and general decline in opioid prescriptions. The timely transition to ADHD drugs was a smart choice that aligns perfectly with Elite's model of niche drugs with high barriers to entry. The team has the facilities well-prepared, and the right products are starting to line up.
The next phase will require a second shift. It's time for our factory to get busy. We've literally got a license to cook crank, so let's really start slinging that speed!
Yes, only traders concerned about the PPS....investors here know what they own... Not worried.. after meeting Nasrat and CFO..I realize they have a end game.. and it ends with a buy out.
I’m here for the buyout price.. Could care less what the current PPS is... as most investors with any experience and vision will agree.
Gee... How are they doing in the CNS field????....LOL LOL LOL
Just opinions with zero facts
Oh ok... well these facts are solid LOL LOL LOL..
I’ll be waiting for some real facts to dispute these numbers for the so called SunGen partnership flop...
Here is exactly what was said..
depends on what the meaning of "flop" is......if it means approvals (with a subsequent fall in pps being ignored) then no..not a flop....but if it means those approvals and the Sungen partnership will likely never amount to real profits because Elite can't compete on price..then yes..a BIG flop....(enlightenment from a friend)
And I have already proven that the SunGen partnership has proved this statement WRONG... so there is that one little FACT.
Are you using the same indicator that said the SunGen partnership was going to be a flop?.. asking for a friend.
Merry Christmas to all.. enjoy your special time with loved ones..
"The greatest glory in living lies not in never falling, but in rising every time we fall." -Nelson Mandela
ELTP definitely a strong candidate for a M& A for 2020...
Nasrat said he would like to find the right company to compliment Elite’s....
Just an example why Nasrat has chosen to sit on the sidelines for now with this current political climate.. Nasrat said DEA is taking a hardline right now.
My patient has to go drive pharmacy to pharmacy today, to see who will fill their pain meds from a Double Board Certified Pain Management specialist.
Their previous pharm has been placed on "restricted access" from DEA.
Yes JJ I was at the shareholders meeting.. You are spot on correct.. matter of fact Nasrat’s words when asked were.... “
We will not pursue them until the political climate changes and I don’t see that happening in the next 2-3 years”
Yes maybe... it might even been him? I didn’t get his name.
Ted at shareholders meeting there was a gentleman there who I believe was retired from Epic and was representing a group of investors from Epic. Not sure how relevant that is but he seemed to have plenty of interest in company.
Nasrat also knew him and spoke of him.
My bad... yeah I’m just under the assumption that Elite will try and partner with that one. I’m just speculating of course.
Well predictions of CRL’s were wrong. Maybe a list of how approvals are bad for companies would be helpful.
Thanks for the great DD... as to your question, Nasrat spoke to this at the shareholders meeting and only said the delay was because they needed more info He expected March now for a timeline but he did say the DEA has taken a hard line against narcotics..
Thanks for the updates
Wondering how this stuff just gets made up.. Nothing but BS.. Adderall XR that was just approved.. umm.. FDA asked Elite for more info on that...so there is that simple fact.
At the shareholders meeting Nasrat said the FDA needed more info... He said it looks like maybe March now.
I heard the same thing that Elite wouldn’t capture market share from the IR Adderall ... yet how would one explains this big jump in revenue?
Last quarter Elite reported $4.6 million in sales, an additional $3.3 million mostly manufacturing revenue from the IR Adderall (Dantrolene was included but the market is tiny so let's not split hairs).
STAY TONED.... the “Goliath Generic Concerta” filing coming soon.. 1.5 billion market size.
“ Nothing credible “... haha... nothing but more and more filings coupled with more and more launches resulting with very successful partnerships being form and rising revenues and manufacturing fees quarter over quarter...
Now record setting revenues
Cash flow positive
Removal of going concern
Yup nothing happening here...too funny
Another thing Nasrat doesn’t get credit for...stockpiling API in advance.
Waiting......????...
Could you please dispute those numbers with a little more detail?,,, LOL LOL
Got this from a poster on another board....This is a break down of expected revenue from the recent approval based on the past couple of financials. I know we are splitting hairs here and they are just rough estimations....the numbers work for me but they are open for debate.
Elite started their immediate release adderall distribution two quarters ago. That market is approx. $365 million and, including Elite, has 12 producers. 3 quarters ago Elite had $1.3 million in sales. Last quarter Elite reported $4.6 million in sales, an additional $3.3 million mostly manufacturing revenue from the IR Adderall (Dantrolene was included but the market is tiny so let's not split hairs). In addition to manufacturing revenue, Elite gets what they categorize as licensing revenue which is the money they receive when Lannett sells to their customers.To use last year's quarter as a guide, Elite did $800,000 in manufacturing revenue and $550,000 in licensing revenue, so out of the $1.3 million revenue, 42% of it was licensing revenue. Last quarter, since there is a lag, measured in months, before licensing revenue hits the books, Elite did $4.2 million in manufacturing revenue and $465,000 in licensing revenue. Just looking at this ratio tells anyone that the lion's share of the new revenue is adderall. Apply the 42% to what we can expect in annual licensing revenue from IR adderall, you get $5.5 million
( $13.3 million annualized IR adderall X .42 ) putting Elite's share of the IR Adderall action at $18.8 million. Out of the $365 million market for the drug, Elite's piece of the IR market is 5.1%. Plug in these numbers to a $1.5 billion ER Adderall market and you get $75 million for Elite in mfg and licensing annual revenue. These are round number comps but if you have your own numbers to back up your opinion I'd like to see them. I'm always interested to hear other opinions or learn something new.
On top of this revenue.... Throw in $600,000 for the sale of Percocet and Norco and $750,000 milestone payment from Lannett for Adderall ER.
Again, at the shareholders meeting Nasrat stated Elite was ready to launch Adderall ER as soon as middle of January and no later than February.
Given the few months lag in manufacturing fees. The end of the year numbers reported in June should be off the hook and the “ Going Concern” removed. We are only six months away now.
When you exercise your shares for tax loss. Make sure you realize you have to stay out of the stock for a month... lol.... good luck with that...lol.. with all the news that is coming..
Agree to disagree... I’ve been hearing cry’s of dilution over the last several quarters. Only to look into the Q’s and see very minimal dilution. FACT... the word used was “dumping”...
Nasrat has the most to lose and gain from the stock price. He is very frugal with all shares and monies concerning Elite. Contrary to what is said on this forum.
Fake news.... all kinds of cash on hand.. no reason to dilute now. Record setting revenues and cash flow positive this quarter... sorry bye..bye
Thanks for your insight WeeZuhl... always great when you weigh in and I for one couldn’t agree with you more.
Snup, there were two auditors present at the shareholders meeting that were the actual ones that issued the going concern.
Nasrat said that the going concern label can not be lifted until after the year end financials.
Got this from a poster on another board....This is a break down of expected revenue from the recent approval based on the past couple of financials. I know we are splitting hairs here and they are just rough estimations....the numbers work for me but they are open for debate.
Elite started their immediate release adderall distribution two quarters ago. That market is approx. $365 million and, including Elite, has 12 producers. 3 quarters ago Elite had $1.3 million in sales. Last quarter Elite reported $4.6 million in sales, an additional $3.3 million mostly manufacturing revenue from the IR Adderall (Dantrolene was included but the market is tiny so let's not split hairs). In addition to manufacturing revenue, Elite gets what they categorize as licensing revenue which is the money they receive when Lannett sells to their customers.To use last year's quarter as a guide, Elite did $800,000 in manufacturing revenue and $550,000 in licensing revenue, so out of the $1.3 million revenue, 42% of it was licensing revenue. Last quarter, since there is a lag, measured in months, before licensing revenue hits the books, Elite did $4.2 million in manufacturing revenue and $465,000 in licensing revenue. Just looking at this ratio tells anyone that the lion's share of the new revenue is adderall. Apply the 42% to what we can expect in annual licensing revenue from IR adderall, you get $5.5 million
( $13.3 million annualized IR adderall X .42 ) putting Elite's share of the IR Adderall action at $18.8 million. Out of the $365 million market for the drug, Elite's piece of the IR market is 5.1%. Plug in these numbers to a $1.5 billion ER Adderall market and you get $75 million for Elite in mfg and licensing annual revenue. These are round number comps but if you have your own numbers to back up your opinion I'd like to see them. I'm always interested to hear other opinions or learn something new.
On top of this revenue.... Throw in $600,000 for the sale of Percocet and Norco and $750,000 milestone payment from Lannett for Adderall ER.
Again, at the shareholders meeting Nasrat stated Elite was ready to launch Adderall ER as soon as middle of January and no later than February.
Given the few months lag in manufacturing fees. The end of the year numbers reported in June should be off the hook and the “ Going Concern” removed. We are only six months away now.